Regorafenib treatment for patients with hepatocellular carcinoma who progressed on sorafenib—A cost-effectiveness analysis

BACKGROUND AND AIMS: Hepatocellular carcinoma (HCC) is one of the leading causes of cancer related deaths. Patients with advanced HCC are treated with sorafenib. A recent randomized controlled trial demonstrated a survival benefit for regorafenib treatment in patients with advanced HCC who had progr...

Descripción completa

Detalles Bibliográficos
Autores principales: Shlomai, Amir, Leshno, Moshe, Goldstein, Daniel A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6224101/
https://www.ncbi.nlm.nih.gov/pubmed/30408106
http://dx.doi.org/10.1371/journal.pone.0207132

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6224101/
https://www.ncbi.nlm.nih.gov/pubmed/30408106
http://dx.doi.org/10.1371/journal.pone.0207132

Ejemplares similares